ZKSCAN3 and urinary bladder cancer: These results not only clarify the molecular basis of ZKSCAN3 driving bladder cancer progression through multi-target regulation but also suggest that RNA interference technology targeting ZKSCAN3 has the potential to be translated into clinical therapeutic strategies.